BPC-157 research overview — structure, published in-vitro signaling, and the analytical documentation US laboratories expect on every batch.
Inside an Australian research workflow, ghk cu is judged less on hype and more on three boring metrics: HPLC purity, mass-spec identity match, and post-reconstitution stability at 2–8 °C. Everything in this article is organised around those three checkpoints.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. It is one of the most heavily researched stable gastric peptides across Australian peptide research literature.
Structure
- Sequence: GEPPPGKPADDAGLV
- 15 amino acids, no disulfide bridges
- Average mass approximately 1419.5 Da
- Notable acid- and enzymatic-stability profile
Published research signaling
Published in-vitro and animal-model literature describes BPC-157 acting on multiple growth-factor and angiogenesis-related pathways, including modulation of VEGFR2 expression and nitric-oxide signaling. These findings are research observations only and do not establish therapeutic outcomes in humans.
What a verified BPC-157 COA shows
- ≥99% HPLC purity
- LC-MS confirmed exact mass
- Counterion (typically acetate) identity and percent
- Bacterial endotoxin per analytical method
Why Bpc 157 peptide matters to research labs
Australian research teams evaluating bpc 157 peptide face three recurring questions before any in-vitro work begins: is the compound what the label claims, will it remain stable across the planned experimental window, and does the supplier's documentation hold up to the standards a principal investigator will sign off on. The remainder of this article is structured around those three questions.
Iron Labs supplies bpc 157 peptide as a lyophilised research material packaged for transit at ambient temperatures and long-term storage at −20 °C. Every batch ships with a lot-specific certificate of analysis covering identity, purity, residual solvents and endotoxin where downstream cell culture work is anticipated.
Typical research applications
Across the published literature, bpc 157 peptide appears most often in three workflow categories. Each has its own documentation profile and storage requirements, which is why a single supplier batch is frequently subdivided across multiple aliquots to limit freeze-thaw cycling.
- In-vitro receptor binding and signalling characterisation, where milligram-scale aliquots are reconstituted fresh on the day of assay.
- Pharmacokinetic and stability modelling, where reconstituted material is sampled at defined time-points and analysed by RP-HPLC.
- Comparative reference work, where bpc 157 peptide is benchmarked against in-house standards or other published research compounds.
Reconstitution and handling reference
Lyophilised bpc 157 peptide is reconstituted with sterile bacteriostatic water using slow, side-of-vial addition to avoid foaming. The vial is allowed to dissolve passively rather than being shaken; mechanical agitation accelerates aggregation in many peptide systems and complicates downstream analytical work. The table below summarises common reconstitution volumes used as documentation references.
| Vial Strength | Diluent Volume | Resulting Concentration |
|---|---|---|
| 5 mg | 1.0 mL bacteriostatic water | 5 mg/mL |
| 10 mg | 1.0 mL bacteriostatic water | 10 mg/mL |
| 10 mg | 2.0 mL bacteriostatic water | 5 mg/mL |
| 30 mg | 3.0 mL bacteriostatic water | 10 mg/mL |
Storage and stability envelope
Lyophilised bpc 157 peptide is documented as stable for 24+ months at −20 °C protected from light. Once reconstituted, the published storage reference for most research peptides in this class is up to 30 days at 2–8 °C when handled aseptically; longer-term storage of reconstituted material is best achieved by single-use aliquoting at −80 °C to remove freeze-thaw variables from later analytical reads.
- Avoid storing reconstituted vials in the refrigerator door — temperature swings shorten usable life.
- Label aliquots with batch ID, reconstitution date and concentration so retrospective audit is straightforward.
- Do not refreeze previously thawed aliquots; integrate single-use volumes into the assay design from the outset.
Quality benchmarks Iron Labs publishes
| Parameter | Iron Labs Spec | Method |
|---|---|---|
| HPLC purity | ≥ 98% | RP-HPLC, UV 214 nm |
| Identity | ± 0.5 Da of theoretical mass | LC-MS or MALDI-TOF |
| Endotoxin | Reported per lot | LAL kinetic chromogenic |
| Counterion | Quantified | Ion chromatography |
| Water content | < 8% (typical lyophilised) | Karl Fischer |
Frequently asked research questions
Is the bpc 157 peptide supplied by Iron Labs intended for human use?
No. All Iron Labs material is supplied strictly for in vitro and laboratory research use. Nothing on this page constitutes medical, veterinary or therapeutic advice.
How is bpc 157 peptide shipped and how long is the transit-stable window?
Material is dispatched as a lyophilised powder, sealed and protected from light. Transit at ambient temperatures over typical Australian courier timelines is well within the published stability envelope for this compound class.
Will a Certificate of Analysis be provided with my bpc 157 peptide order?
Yes. Every batch ships with a lot-specific COA covering identity, purity and the analytical parameters listed in the quality benchmarks section above.
Can I request a specific batch or repeat lot of bpc 157 peptide?
Repeat-lot requests are supported for ongoing research programs; contact the Iron Labs research desk with the previous COA reference and the team will hold inventory from a matching batch where available.
Further reading
Continue with the related Iron Labs research references linked at the foot of this article, or browse the full research catalogue for the compound class profile, lab-results archive and laboratory documentation. For sourcing questions, the research team is available via the Iron Labs contact page.
